Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294310 | 0.95 | CAPN1 (0.35) | CAPN1SIRT2DRD2MMP1MMP2 | |
| SCHEMBL3288125 | 0.95 | CAPN1 (0.35) | CAPN1SIRT2DRD2MMP1MMP2 | |
| SCHEMBL3295787 | 0.95 | CAPN1 (0.35) | CAPN1SIRT2DRD2MMP1MMP2 | |
| SCHEMBL4523800 | 0.90 | CAPN1 (0.36) | CAPN1SIRT2 | |
| SCHEMBL3293178 | 0.87 | DRD2 (0.35) | CAPN1SIRT2DRD2MMP1MMP2 | |
| SCHEMBL3288250 | 0.83 | — | — | |
| SCHEMBL3288380 | 0.79 | TDP1 (0.46) | — | |
| SCHEMBL3290841 | 0.79 | CA14 (0.36) | — | |
| SCHEMBL6889555 | 0.77 | CA14 (0.35) | — | |
| SCHEMBL3287420 | 0.77 | CA1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718157-B1 | Targeted lipid particles | BAKER TERENCE SEWARD | 2010-05-18 | — | — | US | disclosed |
| US-7531676-B2 | Lipids | CELLTECH R & D LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-20060148761-A1 | Lipids | CELLTECH R & D LIMITED | 2006-07-06 | — | — | US | disclosed |
| US-20040024220-A1 | Lipids | CELLTECH R & D LIMITED | 2004-02-05 | — | — | US | disclosed |
| US-6583301-B1 | Bipolar; form complexes with polyanions; delivering bioactive substances such as nucleic acids to cells in vitro and in vivo | CELLTECH R & D LIMITED (GB) | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024220-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | CAPN1 4378/4885SIRT2 3663/4885DRD2 1573/4885 |
| US-20060148761-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | CAPN1 4378/4885SIRT2 3663/4885DRD2 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.